Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Neuronetics, Inc. (STIM) Q1 2024 Earnings Call Transcript
05:16pm, Tuesday, 07'th May 2024
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2024 Results Conference Call May 7, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President, Chief Executive Officer Stev
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
09:41am, Tuesday, 07'th May 2024
Neuronetics (STIM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.38 per share a year ago.
Neuronetics Reports Record First Quarter 2024 Financial and Operating Results
07:30am, Tuesday, 07'th May 2024
MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of trans
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 03'rd May 2024
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
08:31am, Wednesday, 01'st May 2024
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance The Company is highlighting stories from adolescents with major depress
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
04:30pm, Tuesday, 23'rd Apr 2024
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of lif
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
08:31am, Wednesday, 10'th Apr 2024
Lack of early symptom improvement is not predictive of final responder status Lack of early symptom improvement is not predictive of final responder status
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
11:56am, Monday, 01'st Apr 2024
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 27'th Mar 2024
MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
08:30am, Monday, 25'th Mar 2024
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
09:11am, Friday, 08'th Mar 2024
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
08:22am, Thursday, 07'th Mar 2024
MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of lif
Neuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcript
12:19pm, Tuesday, 05'th Mar 2024
Neuronetics, Inc. (NASDAQ:STIM ) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Keith Sullivan - President, Chief Executive Officer Steve Furlong - Chief Financial Offi
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
09:41am, Tuesday, 05'th Mar 2024
Neuronetics (STIM) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
07:30am, Tuesday, 05'th Mar 2024
MALVERN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of tra
